Increases to CEO Compensation Might Be Put On Hold For Now at Venus Remedies Limited (NSE:VENUSREM)

Key Insights

• Venus Remedies will host its Annual General Meeting on 22nd of August
• CEO Ashutosh Jain's total compensation includes salary of ₹7.92m
• Total compensation is 64% above industry average
• Over the past three years, Venus Remedies' EPS grew by 14% and over the past three years, the total shareholder return was 112%

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Performance at Venus Remedies Limited (NSE:VENUSREM) has been reasonably good and CEO Ashutosh Jain has done a decent job of steering the company in the right direction. As shareholders go into the upcoming AGM on 22nd of August, CEO compensation will probably not be their focus, but rather the steps management will take to continue the growth momentum. However, some shareholders may still want to keep CEO compensation within reason.

Check out our latest analysis for Venus Remedies

How Does Total Compensation For Ashutosh Jain Compare With Other Companies In The Industry?

Our data indicates that Venus Remedies Limited has a market capitalization of ₹6.3b, and total annual CEO compensation was reported as ₹8.2m for the year to March 2025. That's a notable increase of 14% on last year. In particular, the salary of ₹7.92m, makes up a huge portion of the total compensation being paid to the CEO.

On comparing similar-sized companies in the Indian Pharmaceuticals industry with market capitalizations below ₹17b, we found that the median total CEO compensation was ₹5.0m. Accordingly, our analysis reveals that Venus Remedies Limited pays Ashutosh Jain north of the industry median.

On an industry level, roughly 98% of total compensation represents salary and 2% is other remuneration. Venus Remedies is focused on going down a more traditional approach and is paying a higher portion of compensation through salary, as compared to non-salary benefits. If total compensation veers towards salary, it suggests that the variable portion - which is generally tied to performance, is lower.

A Look at Venus Remedies Limited's Growth Numbers

Over the past three years, Venus Remedies Limited has seen its earnings per share (EPS) grow by 14% per year. Its revenue is up 9.2% over the last year.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's also good to see modest revenue growth, suggesting the underlying business is healthy. While we don't have analyst forecasts for the company, shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

Has Venus Remedies Limited Been A Good Investment?

Most shareholders would probably be pleased with Venus Remedies Limited for providing a total return of 112% over three years. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.

In Summary...

Ashutosh receives almost all of their compensation through a salary. Seeing that the company has put up a decent performance, only a few shareholders, if any at all, might have questions about the CEO pay in the upcoming AGM. Still, not all shareholders might be in favor of a pay raise to the CEO, seeing that they are already being paid higher than the industry.

CEO compensation is a crucial aspect to keep your eyes on but investors also need to keep their eyes open for other issues related to business performance. We've identified 1 warning sign for Venus Remedies that investors should be aware of in a dynamic business environment.

Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies that have HIGH return on equity and low debt.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.